BRPI0618630A2 - compostos úteis em terapia, formulação farmacêutica que os contém, e seus usos - Google Patents

compostos úteis em terapia, formulação farmacêutica que os contém, e seus usos Download PDF

Info

Publication number
BRPI0618630A2
BRPI0618630A2 BRPI0618630-0A BRPI0618630A BRPI0618630A2 BR PI0618630 A2 BRPI0618630 A2 BR PI0618630A2 BR PI0618630 A BRPI0618630 A BR PI0618630A BR PI0618630 A2 BRPI0618630 A2 BR PI0618630A2
Authority
BR
Brazil
Prior art keywords
pyrazol
yloxy
methanesulfonylmethyl
formula
dicyclopropyl
Prior art date
Application number
BRPI0618630-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Paul Anthony Bradley
Kevin Neil Dack
Patrick Stephen Johnson
Sara Elizabeth Skerratt
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of BRPI0618630A2 publication Critical patent/BRPI0618630A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18One oxygen or sulfur atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0618630-0A 2005-11-08 2006-10-26 compostos úteis em terapia, formulação farmacêutica que os contém, e seus usos BRPI0618630A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73509105P 2005-11-08 2005-11-08
US60/735,091 2005-11-08
PCT/IB2006/003080 WO2007054770A2 (fr) 2005-11-08 2006-10-26 Composes utiles en therapie

Publications (1)

Publication Number Publication Date
BRPI0618630A2 true BRPI0618630A2 (pt) 2011-09-06

Family

ID=37909834

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0618630-0A BRPI0618630A2 (pt) 2005-11-08 2006-10-26 compostos úteis em terapia, formulação farmacêutica que os contém, e seus usos

Country Status (35)

Country Link
US (2) US7309712B2 (fr)
EP (1) EP1948615B1 (fr)
JP (1) JP4234786B1 (fr)
KR (1) KR100997595B1 (fr)
CN (1) CN101304974A (fr)
AP (1) AP2008004463A0 (fr)
AR (1) AR056780A1 (fr)
AT (1) ATE537150T1 (fr)
AU (1) AU2006313478A1 (fr)
BR (1) BRPI0618630A2 (fr)
CA (1) CA2628844C (fr)
CR (1) CR9959A (fr)
CY (1) CY1112286T1 (fr)
DK (1) DK1948615T3 (fr)
DO (1) DOP2006000245A (fr)
EA (1) EA014693B1 (fr)
EC (1) ECSP088431A (fr)
ES (1) ES2376252T3 (fr)
GT (1) GT200600478A (fr)
HN (1) HN2006037713A (fr)
IL (1) IL190806A0 (fr)
MA (1) MA29940B1 (fr)
NL (1) NL2000299C2 (fr)
NO (1) NO20082504L (fr)
PE (1) PE20070642A1 (fr)
PL (1) PL1948615T3 (fr)
PT (1) PT1948615E (fr)
RS (1) RS20080191A (fr)
SI (1) SI1948615T1 (fr)
TN (1) TNSN08202A1 (fr)
TW (1) TWI321563B (fr)
UA (1) UA90763C2 (fr)
UY (1) UY29904A1 (fr)
WO (1) WO2007054770A2 (fr)
ZA (1) ZA200803670B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ332762A (en) 1996-07-24 2000-09-29 Warner Lambert Co Isobutylgaba and its derivatives for the treatment of pain
BRPI0618630A2 (pt) * 2005-11-08 2011-09-06 Pfizer Ltd compostos úteis em terapia, formulação farmacêutica que os contém, e seus usos
EP2081905B1 (fr) 2006-07-28 2012-09-12 Boehringer Ingelheim International GmbH Composés sulfonyles modulant le récepteur cb2
JP5030114B2 (ja) 2006-09-25 2012-09-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Cb2受容体をモジュレートする化合物
WO2008135824A1 (fr) * 2007-05-02 2008-11-13 Pfizer Limited Composés d'oxyalkylpyrazole utiles en thérapie
US8546563B2 (en) 2007-11-07 2013-10-01 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
JP2010043063A (ja) 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
EP2418207A1 (fr) * 2008-05-13 2012-02-15 Boehringer Ingelheim International GmbH Composés de sulfone qui modulent le récepteur CB2
EP2326629B1 (fr) 2008-07-10 2013-10-02 Boehringer Ingelheim International GmbH Composés sulfones qui modulent le récepteur cb2
CN102164916A (zh) 2008-09-25 2011-08-24 贝林格尔.英格海姆国际有限公司 选择性调节cb2受体的磺酰基化合物
US8299103B2 (en) 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
JP5756800B2 (ja) 2009-06-16 2015-07-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Cb2受容体を調節するアゼチジン2−カルボキサミド誘導体
WO2011037795A1 (fr) 2009-09-22 2011-03-31 Boehringer Ingelheim International Gmbh Composés à modulation sélective du récepteur cb2
US20110136815A1 (en) * 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
JP2013517271A (ja) 2010-01-15 2013-05-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Cb2受容体を調節する化合物
EP2542539B1 (fr) 2010-03-05 2014-02-26 Boehringer Ingelheim International GmbH Composés tétrazoles qui modulent sélectivement le récepteur cb2
US20110263606A1 (en) * 2010-04-26 2011-10-27 Horst Zerbe Solid oral dosage forms comprising tadalafil
EP2595959B1 (fr) 2010-07-22 2015-11-04 Boehringer Ingelheim International GmbH Composés sulfonylés qui modulent le récepteur cb2
EP2803668A1 (fr) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Nouveau (cyano-dimethyl-methyl)-isoxazoles et - [1,3,4] thiadiazoles
US20210395235A1 (en) * 2018-10-18 2021-12-23 Nanjing Sanhome Pharmaceutical Co., Ltd. COMPOUND AS TGF-beta R1 INHIBITOR AND APPLICATION THEREOF
RU2711615C1 (ru) * 2019-09-12 2020-01-17 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт акушерства, гинекологии и репродуктологии имени Д.О. Отта" Способ лечения эндометриоза на основании экспериментальной модели у крыс
CN111269097B (zh) * 2020-04-02 2023-02-17 苏州爱玛特生物科技有限公司 一种多元环双取代的1,3-丙二酮类化合物的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6281638A (ja) * 1985-10-07 1987-04-15 Fuji Photo Film Co Ltd ハロゲン化銀カラ−写真感光材料
JPS63313784A (ja) * 1987-03-12 1988-12-21 Zeria Shinyaku Kogyo Kk 新規ピラゾール誘導体およびその製造法ならびにこれを有効成分とする抗潰瘍剤
DE4414792A1 (de) * 1993-08-11 1995-02-16 Bayer Ag Arzneimittel enthaltend 1-Thiocarbamoyl-5-hydroxypyrazolen und deren Verwendung als Mittel zur Bekämpfung des septischen Schocks
PL217224B1 (pl) * 2001-04-10 2014-06-30 Pfizer Kompozycja farmaceutyczna oraz jej zastosowanie
GB0229618D0 (en) * 2002-12-19 2003-01-22 Cancer Rec Tech Ltd Pyrazole compounds
BRPI0618630A2 (pt) * 2005-11-08 2011-09-06 Pfizer Ltd compostos úteis em terapia, formulação farmacêutica que os contém, e seus usos

Also Published As

Publication number Publication date
DOP2006000245A (es) 2007-06-30
ES2376252T3 (es) 2012-03-12
CA2628844C (fr) 2011-12-06
CN101304974A (zh) 2008-11-12
RS20080191A (en) 2009-07-15
US7425569B2 (en) 2008-09-16
EP1948615B1 (fr) 2011-12-14
WO2007054770A3 (fr) 2007-10-04
US20080085919A1 (en) 2008-04-10
WO2007054770A2 (fr) 2007-05-18
TWI321563B (en) 2010-03-11
HN2006037713A (es) 2010-06-09
UY29904A1 (es) 2007-06-29
DK1948615T3 (da) 2012-02-06
GT200600478A (es) 2007-06-08
EA014693B1 (ru) 2010-12-30
AP2008004463A0 (en) 2008-06-30
KR20080056761A (ko) 2008-06-23
MA29940B1 (fr) 2008-11-03
NL2000299C2 (nl) 2007-11-20
US20070105909A1 (en) 2007-05-10
EA200801053A1 (ru) 2008-10-30
ZA200803670B (en) 2009-03-25
NO20082504L (no) 2008-06-05
PE20070642A1 (es) 2007-08-24
ATE537150T1 (de) 2011-12-15
KR100997595B1 (ko) 2010-11-30
JP4234786B1 (ja) 2009-03-04
TW200804295A (en) 2008-01-16
PL1948615T3 (pl) 2012-04-30
AU2006313478A1 (en) 2007-05-18
IL190806A0 (en) 2008-11-03
CR9959A (es) 2008-08-01
ECSP088431A (es) 2008-06-30
AR056780A1 (es) 2007-10-24
JP2009514938A (ja) 2009-04-09
PT1948615E (pt) 2012-02-03
SI1948615T1 (sl) 2012-02-29
CA2628844A1 (fr) 2007-05-18
CY1112286T1 (el) 2015-12-09
UA90763C2 (ru) 2010-05-25
NL2000299A1 (nl) 2007-05-09
TNSN08202A1 (fr) 2009-10-30
EP1948615A2 (fr) 2008-07-30
US7309712B2 (en) 2007-12-18

Similar Documents

Publication Publication Date Title
ES2376252T3 (es) Derivados de pirazol útiles para el tratamiento de enfermedades ginecológicas.
US7482375B2 (en) Compounds useful in therapy
US8232269B2 (en) Amide compounds useful in therapy
DE69425442T2 (de) 1,3,5- trisubstituierte pyrazolverbindungen zur behandlung von entzündungen
US20020111374A1 (en) Estrogen receptor modulators
BRPI0808450A2 (pt) Composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto
TW200806651A (en) Pyrazoles as 11-beta-HSD-1
US20080096950A1 (en) Compounds Useful In Therapy
MX2011004903A (es) Pirrolidinas.
WO2008135824A1 (fr) Composés d'oxyalkylpyrazole utiles en thérapie
JP2005515171A (ja) 5−ヘテロ原子含有ピラゾールの効率的な合成法

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2214 DE 11/06/2013.